Show simple item record

dc.contributor.authorBancroft, EK
dc.contributor.authorSaya, S
dc.contributor.authorPage, EC
dc.contributor.authorMyhill, K
dc.contributor.authorThomas, S
dc.contributor.authorPope, J
dc.contributor.authorChamberlain, A
dc.contributor.authorHart, R
dc.contributor.authorGlover, W
dc.contributor.authorCook, J
dc.contributor.authorRosario, DJ
dc.contributor.authorHelfand, BT
dc.contributor.authorHutten Selkirk, C
dc.contributor.authorDavidson, R
dc.contributor.authorLongmuir, M
dc.contributor.authorEccles, DM
dc.contributor.authorGadea, N
dc.contributor.authorBrewer, C
dc.contributor.authorBarwell, J
dc.contributor.authorSalinas, M
dc.contributor.authorGreenhalgh, L
dc.contributor.authorTischkowitz, M
dc.contributor.authorHenderson, A
dc.contributor.authorEvans, DG
dc.contributor.authorBuys, SS
dc.contributor.authorIMPACT Study Steering Committee,
dc.contributor.authorIMPACT Collaborators,
dc.contributor.authorEeles, RA
dc.contributor.authorAaronson, NK
dc.date.accessioned2018-06-21T09:40:48Z
dc.date.issued2019-02-01
dc.identifier.citationBJU international, 2019, 123 (2), pp. 284 - 292
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1891
dc.identifier.eissn1464-410X
dc.identifier.doi10.1111/bju.14412
dc.description.abstractOBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.
dc.formatPrint-Electronic
dc.format.extent284 - 292
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectIMPACT Study Steering Committee
dc.subjectIMPACT Collaborators
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectRisk Factors
dc.subjectCase-Control Studies
dc.subjectLongitudinal Studies
dc.subjectHealth Knowledge, Attitudes, Practice
dc.subjectDepression
dc.subjectAnxiety
dc.subjectPerception
dc.subjectPsychiatric Status Rating Scales
dc.subjectMutation
dc.subjectGenes, BRCA1
dc.subjectGenes, BRCA2
dc.subjectQuality of Life
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectEarly Detection of Cancer
dc.subjectSurveys and Questionnaires
dc.titlePsychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
dc.typeJournal Article
dcterms.dateAccepted2018-05-21
rioxxterms.versionofrecord10.1111/bju.14412
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU international
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume123
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Dearnaley)
icr.researchteamOncogenetics
icr.researchteamStereotactic and Precision Body Radiotherapy
dc.contributor.icrauthorEeles, Rosalind


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0